Oncternal Therapeutics Inc Total Assets
Oncternal Therapeutics Inc total assets. Based on the latest financial reports, Oncternal Therapeutics Inc (ONCT) holds total assets worth $15.60 Million USD as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ONCT stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Oncternal Therapeutics Inc (1999–2023)
Total assets of Oncternal Therapeutics Inc from 1999 to 2023. This chart illustrates how Oncternal Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Oncternal Therapeutics Inc (ONCT) share price today for real-time trading data and today's change.
Oncternal Therapeutics Inc - Asset Composition Analysis
Oncternal Therapeutics Inc Total Assets Breakdown (December 2023)
Oncternal Therapeutics Inc total assets breakdown as of December 2023. Oncternal Therapeutics Inc's total assets of $15.60 Million consist of 98.2% current assets and 1.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 18.2% |
| Accounts Receivable | $632.00K | 1.7% |
| Inventory | $1.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1999–2023)
This chart illustrates how Oncternal Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore how liquid is Oncternal Therapeutics Inc's working capital to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oncternal Therapeutics Inc's current assets represent 98.2% of total assets in 2023, an increase from 91.9% in 1999.
- Cash Position: Cash and equivalents constituted 18.2% of total assets in 2023, down from 91.9% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1999.
- Asset Diversification: The largest asset category is accounts receivable at 1.7% of total assets.
Oncternal Therapeutics Inc Competitors by Total Assets
Key competitors of Oncternal Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Oncternal Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.39 | 8.25 | 2.83 |
| Quick Ratio | 2.39 | 8.28 | 2.83 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.99 Million | $37.34 Million | $13.45 Million |
Oncternal Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Oncternal Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.17 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -46.5% |
| Total Assets | $36.73 Million |
| Market Capitalization | $1.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Oncternal Therapeutics Inc's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Oncternal Therapeutics Inc's assets decreased by 46.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oncternal Therapeutics Inc (1999–2023)
The table below shows the annual total assets of Oncternal Therapeutics Inc from 1999 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $36.73 Million | -46.50% |
| 2022-12-31 | $68.65 Million | -26.64% |
| 2021-12-31 | $93.58 Million | -21.23% |
| 2020-12-31 | $118.81 Million | +446.40% |
| 2019-12-31 | $21.74 Million | -30.58% |
| 2018-12-31 | $31.32 Million | -32.26% |
| 2017-12-31 | $46.24 Million | +88.70% |
| 2016-12-31 | $24.50 Million | -23.51% |
| 2015-12-31 | $32.03 Million | -36.76% |
| 2014-12-31 | $50.65 Million | +224.58% |
| 2013-12-31 | $15.61 Million | -72.99% |
| 2012-12-31 | $57.77 Million | -26.11% |
| 2011-12-31 | $78.18 Million | +21.69% |
| 2010-12-31 | $64.25 Million | +11.31% |
| 2009-12-31 | $57.72 Million | -46.61% |
| 2008-12-31 | $108.11 Million | -32.32% |
| 2007-12-31 | $159.73 Million | +23.58% |
| 2006-12-31 | $129.25 Million | +56.08% |
| 2005-12-31 | $82.81 Million | +13.31% |
| 2004-12-31 | $73.08 Million | +322.20% |
| 2003-12-31 | $17.31 Million | +72.58% |
| 2002-12-31 | $10.03 Million | -0.86% |
| 2001-12-31 | $10.12 Million | +216.06% |
| 2000-12-31 | $3.20 Million | +90.76% |
| 1999-12-31 | $1.68 Million | -- |
About Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS… Read more